SCHEMBL9007912

SCHEMBL9007912

CN1/C(=C/C2=C(O)/C(=C/C3=[N+](C)c4ccccc4C3(C)C)C2=O)C(C)(C)c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 11/20 0.44
HTT P42858 10/20 0.44
MAPT P10636 14/20 0.44
L3MBTL1 Q9Y468 5/20 0.44
MAPK1 P28482 5/20 0.44
KDM4E B2RXH2 5/20 0.44
TDP1 Q9NUW8 3/20 0.44
MEN1 O00255 12/20 0.42
KMT2A Q03164 12/20 0.42
SMN1; SMN2 Q16637 6/20 0.42
ALDH1A1 P00352 5/20 0.42
POLB P06746 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
THRB P10828 2/20 0.42
RECQL P46063 2/20 0.42
PKM P14618 1/20 0.42
XBP1 P17861 1/20 0.42
PPARG P37231 1/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13084302 1.00 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL12690873 1.00 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL12698830 1.00 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL15996382 1.00 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL15490662 0.99 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL13569279 0.97 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL13109123 0.97 LMNA (0.44) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL19815887 0.89 LMNA (0.42) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL19815888 0.89 LMNA (0.42) LMNAHTTMAPTL3MBTL1MAPK1
SCHEMBL14199095 0.89 MAPT (0.41) LMNAHTTMAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CANON KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
US-8570597-B2 Image forming apparatus and image forming method which enhance graininess and also reduce a total toner amount without deteriorating image quality in image formation using toner of high chroma KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2013-10-29 US disclosed
US-8241826-B2 Full-color image forming method KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-08-14 US disclosed
US-8187782-B2 Full color image formation process KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-05-29 US disclosed
US-20110216381-A1 IMAGE FORMING APPARATUS AND IMAGE FORMING METHOD KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2011-09-08 US disclosed
US-20100252433-A1 NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES NATIONAL SCIENCE FOUNDATION 2010-10-07 US disclosed
US-20100252433-A1 NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES NATIONAL SCIENCE FOUNDATION 2010-10-07 US disclosed
US-20100159383-A1 METHOD FOR PRODUCING COLOR PRINT KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2010-06-24 US disclosed
US-20090291376-A1 FULL-COLOR IMAGE FORMING METHOD KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2009-11-26 US disclosed
US-20090291375-A1 FULL COLOR IMAGE FORMATION PROCESS KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100252433-A1 NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES PTMS, CHAMP1, RAB5IF LMNA 3234/4885HTT 4288/4885MAPT 1476/4885
US-20160018389-A1 MACROPHAGE IDENTIFICATION AGENT, AND IDENTIFICATION METHOD, SORTING METHOD, EVALUATION METHOD, SCREENING METHOD AND KIT USING THE MACROPHAGE IDENTIFIER AGENT CD68, MSR1, MYADM LMNA 2744/4885HTT 4857/4885MAPT 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.